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Abstract—Risk prediction is central to both clinical medicine 
and public health. While many machine learning models have 
been developed to predict mortality, they are rarely applied in 
the clinical literature, where classification tasks typically rely 
on logistic regression. One reason for this is that existing 
machine learning models often seek to optimize predictions by 
incorporating features that are not present in the databases 
readily available to providers and policy makers, limiting 
generalizability and implementation. Here we tested a number 
of machine learning classifiers for prediction of six-month 
mortality in a population of elderly Medicare beneficiaries, 
using an administrative claims database of the kind available 
to the majority of health care payers and providers. We show 
that machine learning classifiers substantially outperform 
current widely-used methods of risk prediction—but only 
when used with an improved feature set incorporating insights 
from clinical medicine, developed for this study. Our work has 
applications to supporting patient and provider decision 
making at the end of life, as well as population health-oriented 
efforts to identify patients at high risk of poor outcomes. 
 
Index Terms— Machine learning, mortality, prediction, 
health care.  
I. INTRODUCTION 
Physicians and patients routinely face important decisions 
regarding medical care at the end of life, ranging from 
aggressive curative treatment to comfort-oriented palliative 
care. Such treatment decisions depend heavily on a patient’s 
expected survival, or prognosis: high-risk interventions for 
example surgery or chemotherapy may be reasonable 
options for patients with longer expected survival, but are 
less well-suited to patients with poor prognoses—who 
assume all the risks of the intervention but are unlikely to 
live long enough to realize its potential benefits. The 
adoption of the Affordable Care Act has heightened interest 
in strategies to target poor-prognosis patients for 
interventions to improve quality of care at the end of life, 
and at the same time reduce costs. Thus the availability of 
accurate prediction tools is important to support both 
physician and patient decision making at the end of life, as 
well as policy-level population health management efforts.  
 Despite the importance of accurate risk prediction, 
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there are few examples of mortality prediction models being 
used in a real-life clinical or policy setting. This is for at 
least two reasons. First, current approaches to identification 
of high-risk patients in the clinical literature and 
classification tasks in general rely on logistic regression to 
predict mortality, mostly using small datasets and small 
feature sets [1]. Besides producing biased coefficients, this 
on average underestimates predicted probability of rare 
outcomes like death [2]. In addition, several basic 
assumptions of logistic regression are problematic in the 
high dimensional, highly correlated feature sets needed to 
accurately characterize medical illnesses, including 
illnesses, health care utilization, and demographics.  
 Second, while the machine learning (ML) literature 
contains many tools for predicting clinical outcomes, these 
typically rely heavily on feature sets derived from test 
results or de novo data collection from patients—examples 
include genomic data [3], vital signs [4], laboratory tests [5] 
or medical chart text [6]—which are typically not available 
in databases used by clinicians and policy makers, resulting 
in a technically excellent classifier with no clear path to 
implementation in a real health care environment. 
Conversely, despite the obvious practical advantages of 
using routinely collected data available to most health care 
providers with respect to implementation, administrative 
data have a poor track record of success for risk prediction. 
Indeed, models using these administrative data generate 
such poor predictions that a recent review in a leading 
medical journal could not recommend them for predicting 
outcomes in populations of older adults [1]. 
 We set out to explore the performance of several ML 
classifiers for the prediction of short-term (six month) 
survival with administrative health data, building on insights 
from prior studies utilizing ML techniques with 
administrative data to answer similar questions [7], [8]. We 
hypothesized that some of the limitations of prediction using 
administrative data could be overcome with careful 
pre-processing and engineering of features, drawing on 
insights from machine learning [9] and clinical medicine 
[10] literature. We thus constructed an augmented set of 
variables capturing patients’ comorbidity (disease burden), 
healthcare utilization, and functional status (ability to live 
and function independently). We tested these augmented 
features with a range of commonly used ML algorithms, in 
combination with class balancing techniques, and evaluated 
their performance compared to traditional measures of 
comorbidity commonly used to predict mortality in similar 
datasets. Our work could be used to aid physician and 
patient decisions regarding end of life care. On an aggregate 
population level, it could also serve to identify patients at a 
high risk of poor outcomes, as an input to efforts to manage 
and improve the health of populations.  
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II. DATA 
We used Medicare claims data, which capture patient 
demographics, healthcare utilization, and recorded 
diagnoses from the time of Medicare enrollment till death, 
to develop our model. We used a nationally-representative 
5% sample of all Medicare fee-for-service beneficiaries in 
2010 and retained those over 65 years old living in the 
continental United States. We included only those alive and 
not enrolled in the Medicare hospice benefit (implying 
known terminal disease) on an arbitrary date, t0 (July 1, 
2010), to mimic a real life situation in which predictions are 
needed at an arbitrary point in time. 
 We segmented the population into non-mutually 
exclusive cohorts based on presence of major individual 
diseases, as traditionally defined in the health services 
research literature [10], based on whether or not a patient 
was diagnosed with the disease in the year prior to t0.  We 
selected four disease cohorts—congestive heart failure 
(CHF), dementia, chronic obstructive pulmonary disease 
(COPD), and any tumor, all major causes of death and 
disability nationally—to explore how predictions vary 
across a range of underlying medical pathologies and 
mortality rates. We randomly chose 20,000 beneficiaries in 
each disease group from the national sample (of 
approximately  2, 0.8, 2.7, 2.3 million, respectively), and 
split each equally into development and validation datasets.  
 We used death dates from the Medicare data to define 
our outcome of interest, death in the six months after t0. 
Six-month survival is the major eligibility criterion for the 
hospice benefit, making it a useful interval for both 
physicians and patients to start considering the goals of end 
of life care. We used a one-year look-back period before t0 
to create features for predicting death. Over this period, we 
extracted information about patient demographics, 
healthcare utilization, comorbidity, durable medical 
equipment and medical diagnoses using inpatient and 
outpatient, home health and durable medical equipment 
claims.  
A. Traditional Model and Variables 
In order to compare the performance of our final classifier 
to existing practices, we used a model developed by Gagne 
et al [10] which was identified by a recent review as the best 
prognostic tool [1] for predicting mortality using 
administrative data. This model used age, sex, and a set of 
20 indicator variables corresponding to individual diseases 
or conditions (a combination of the commonly-used 
Elixhauser and Charlson indices).1 Indicators were initially 
set to zero. If an International Classification of Disease 
(ICD) code corresponding to any of these comorbidities was 
present on any claim in the one-year look-back period 
before t0 the indicator was set to one, accounting for 
outpatient ‘rule-out’ diagnoses as is usual [11]. 
B. Augmented Feature Set Creation  
We set out to create an ‘augmented’ set of clinically 
relevant health measures that captured disease severity and 
progression with time as well as functional status.  
 In order to capture disease progression, we replaced 
each of the 20 comorbidity indicator variables from the 
traditional model with two count variables representing the 
total number of medical encounters (such as clinic or 
 
1 The original paper by Gagne et al. [10] used a sample from a single US 
state, whereas we use a sample drawn from across the US. We included a 
vector of 51 state indicator variables for each state in continental US as 
well as D.C. to account for this difference.  
emergency room visits and inpatient or skilled nursing 
facility stays) involving that comorbidity, in two time 
periods: 1-3 months, and 3-12 months prior to t0. Unlike 
traditional indicator variables these features capture not only 
presence or absence of a disease, but its severity (measured 
by number of encounters) and evolution over time (captured 
by two features for two discrete time periods, a recent period 
and a baseline period).  
Figure 1 shows the difference between the traditional and 
the augmented variable sets, for two hypothetical patients 
with different trajectories of disease x over the look-back 
period. Ticks on the x-axis show the individual 
patient–physician encounters related to disease x, dashed 
and solid lines show the values of the traditional and 
augmented variables respectively.  In this scenario, Patient 1 
experienced progressively worsening disease while Patient 
2’s disease was treated or resolved. These two patients 
would be have the same value on a traditional measure of 
disease x, despite clear difference in their disease 
trajectory—and likely prognosis—while the augmented 
variables capture the two different trajectories. We initially 
chose these specific time periods (1-3 and 3-12) based on 
visually inspecting healthcare utilization patterns, and 
observing a sharp increase in the number of total diagnoses 
three months before death (see Figures 2 & 3). We later 
empirically validated our choice as outlined in the analysis 
section.  
 
Fig. 1. Augmented vs. traditional variables 
 
 We also developed a new set of features measuring 
functional status, a patient’s ability to live and function 
independently and without assistance. Functional status is 
known to have considerable prognostic importance [12], 
[13] but does not figure into any existing set of 
comorbidities derived from administrative data. We 
identified claims for durable medical equipment (e.g., 
walker, wheelchair, home oxygen) as well as non-specific 
ICD codes (e.g., 728.87 muscle weakness, general; 783.7 
failure to thrive-adult). Each of these measures was included 
as count variables, split into 1-3 and 3-12 time periods. We 
also included counts of utilization of health care services 
including clinic and ED visits, inpatient hospitalizations, 
home health assistance, and skilled nursing facility for each 
  
of the two time periods. Finally, we added income and race, 
which have previously been identified as predictors of 
mortality [14], likely because they account for unmeasured 
differences in baseline illness and access to care. The full 
list of variables is included in Table 1.  
 
TABLE I. COMPARISON BETWEEN VARIABLES IN THE AUGMENTED AND 
TRADITIONAL VARIABLE SETS † 
  Traditional   Augmented 
Patient demographics    
Age   +  + 
Sex + + 
State of residence  + + 
Race  -   + 
Income deciles 
 - + 
Disease groups: Alcohol 
abuse, deficiency anemia, 
cardiac arrhythmias, 
coagulopathy, complicated 
diabetes, dementia, fluid & 
electrolyte disorders, 
hemiplegia, HIV/AIDS, 
hypertension, liver disease, 
metastatic cancer, CHF, 
psychosis, COPD, chronic 
pulmonary disease, peripheral 
vascular disorder, renal 
failure, tumor and weight loss 
 
Dummy 
variable  
Two count variables 
for each disease group: 
one for 1-3 and 
another for 3-12 
months before July 1st 
Functional status: 
Aerodigestive-GI/GU,  
aerodigestive-nutrition, 
aerodigestive-respiratory, 
general weakness, general 
mobility, cognition, 
sensorium and speech  
- 
Two count variables 
for each group: one for 
1-3 and another for 
3-12 months before 
July 1st 
Durable medical equipment: 
bed, cane/walker, O2  and 
wheelchair 
- 
Two count variables 
for each durable 
medical equipment: 
one for 1-3 and 
another for 3-12 
months before July 1st 
Utilization*: Home health 
days, inpatient days, skilled 
nursing facility admissions, 
inpatient admissions, clinic 
and emergency room visits  
- 
Two count variables 
for each encounter: 
one for 1-3 and 
another for 3-12 
months before July 1st 
† The plus sign (+) signifies presence while the minus sign (-) signifies 
absence  
*Skilled nursing facility stays were represented by two indicator 
variables, one for 1-3 and another for 3-12 months before July 1st, 
instead of count variables due to limitations of claims information on 
these encounters 
CHF denotes congestive heart failure  
COPD denotes chronic obstructive pulmonary disease  
ICD denotes International Classification of Disease codes 
GI/GU denotes gastrointestinal and genitourinary impairments  
 
III. ANALYSIS 
Since few papers have applied ML to administrative 
claims data, we first surveyed current literature to identify 
the most common supervised learning techniques used in 
similar settings with high-dimensional, highly correlated 
features, and an imbalanced binary outcome [15], [16]. We 
implemented six classifiers: naïve Bayes, support vector 
machines (SVM), K nearest neighbors (k-NN), artificial 
neural nets (ANN), random forests (RF) and logistic 
regression, both with L1 regularization (lasso)  and without.2 
We analyzed each of the four disease cohorts separately, 
using the same development and validation samples to 
compare the different classifiers.  
 We chose area under receiver operating curve3 (AUC) 
as our primary performance measure for all classifiers. 
Given that six-month mortality was a rare outcome in all 
four disease cohorts (10% or under), optimizing accuracy 
could have resulted in a fairly accurate model that simply 
predicted that all subjects would live. In all cases, we split 
the development dataset into two randomly chosen mutually 
exclusive samples of equal size. The first was used to train 
models (‘training sample’) while the second was used to 
tune the parameters (‘tuning sample’). We report results 
only for the validation dataset.  
 For each of the six classifiers, we identified the optimal 
combination of tuning parameters using a greedy search 
algorithm. We first trained the model using the training 
sample setting all the model parameters to their default 
values, then changed one parameter at a time and chose the 
value that maximized AUC of the tuning sample. We used 
the optimal value when tuning the second parameter and so 
forth. Second, given class imbalance in this dataset, we 
experimented with several up- and down-sampling strategies 
in order to present the classifier with a balanced dataset of 
alive and dead patients: up-sampling, creating duplicates of 
the minority class, and down-sampling, choosing a random 
sample of the non-events, both resulting in class balance in 
the final training dataset. In each of these cases, we 
up-sampled or down-sampled the training dataset and used 
the original tuning dataset to test the performance of the 
classifier. We repeated this process for each of the four 
disease cohorts and for each variable set; the traditional and 
the augmented.  
 For each method and each disease cohort we created 
the model using the development dataset then predicted the 
outcomes for the 10,000 beneficiaries in the validation 
dataset and finally calculated the AUC as well as a 
bootstrapped standard deviation using 1,000 replicates. We 
identified the best performing model by identifying the 
maximum AUC for each method and each disease cohort. 
After identifying the best performing classifier, we 
empirically validated our choice to discretize the augmented 
variables into 1-3 and 3-12 months before t0. Using the same 
development and validation samples, we created 11 alternate 
variable sets, similar in principle to the augmented variables 
described above, but discretizing over different time 
periods: 1-2 months and 2-12 months, 1-4 and 4-12 and so 
forth (one of these sets was simply a vector of count 
variables summed over months 1-12). We then trained the 
best classifier using the same training samples with these 11 
additional variable sets and used predictions from the 
validation sample to calculate the AUC. 
IV. RESULTS 
Mortality rates in the four development samples were 
 
2 All analyses were done using R version 3.1.0. Naïve bayes classifiers 
were built using the  klaR package, SVMs using the kernlab package, 
k-NNs using the caret package, ANN using the nnets package, RFs using 
the randomForest package, lasso using the glmnet package and finally 
logistic regressions using the stats package.  
3 The AUC reflects the probability that given two patients, one with 
positive outcome (death in the 6 months after July 1) and the other with a 
negative outcome (survival during the same period), the model will assign a 
higher probability of death to the former.  
  
4.7%, 4.9%, 7.7% and 10.1%, for the tumor, COPD, CHF 
and dementia cohorts respectively. Rates in the validation 
samples were similar: 4.4%, 4.8%, 7.7%, and 9.7%. 
Table 2 shows the AUC (validation) using the augmented 
and traditional variables for each family of classifiers. We 
only present the results from the tumor group since relative 
performance of classifiers was largely similar across the 
four disease cohorts. Overall, the best performing model 
was the RF using the augmented variables, which had an 
AUC of 0.826 (SD = 0.010) using the pre-specified split on 
0-3 and 3-12 months, and higher at an AUC of 0.828 (SD = 
0.010) using the best split, which we determined 
retrospectively using validation data. All classifiers 
performed better when trained using the augmented 
variables. Logistic regression with L1 regularization was the 
best performing classifier using traditional variables.  
The results in table 2 show the performance of the best 
model within each family of classifiers, from the validation 
dataset. For the random forest, the best model configuration 
used 1000 trees, with each split using sqrt(m) variables 
(where m is the total number of variables in the model, 
which varied between traditional and augmented sets) and a 
terminal node size of 1. We used a different randomly 
chosen balanced subsample of the data to grow each tree. 
The best lasso model was created using a down-sampled 
dataset for the augmented variables and the original sample 
using traditional variables. The original sample, without any 
re-sampling, gave the best results when training the naïve 
Bayes, regardless of which variable set was being used. The 
neural nets with 2 hidden layers, using a down-sampled 
dataset performed best with the traditional and augmented 
variables. We used 10 fold cross validation in the training 
dataset to estimate the best number of neighbors for the 
k-NN, which performed best with a down-sampled dataset 
for both variable sets. As for the SVM the best performing 
model used a radial basis function to map the data onto a 
higher dimension. The best sampling method for the logistic 
regression was down-sampling when using the augmented 
variables and up-sampling when using the traditional 
variables. Further data on the specific model fits is available 
from the authors on request.  
 
TABLE II: VALIDATION AUC OF THE TUMOR COHORT ACROSS 
DIFFERENT CLASSIFIERS 
  
Augmented 
variables  
Traditional 
variables  
Classifier AUC SD AUC SD 
Random Forest  0.826 0.010 0.774 0.012 
Lasso 0.810 0.011 0.780 0.012 
Naïve bayes  0.794 0.011 0.757 0.012 
Neural nets  0.772 0.012 0.481 0.014 
kNN 0.767 0.012 0.712 0.014 
SVM 0.761 0.011 0.667 0.013 
Logistic regression  0.563 0.053 0.727 0.014 
Table II shows AUC and bootstrapped standard deviation of the 
tumor validation dataset for the best performing combination of 
tuning parameters and sampling techniques for each family of 
classifiers  
 
Overall performance of all classifiers varied considerably 
across the four disease cohorts as shown in Table 3, which 
shows the validation AUC by disease cohort using the 
augmented variables split at 1-3 and 3-12 as well as the best 
split which varied by disease cohort. The tumor group had 
the highest AUC even though it suffered from the highest 
class imbalance.  We tested the performance of the 
additional 11 variable sets that were created to test time 
period aggregations other than 1-3 and 3-12. We found that 
splitting the count variables into 1 month and 1-12 months 
produced the highest AUCs in the tumor (AUC= 0.828), 
COPD (AUC=0.814), and CHF (AUC=0.756) while 
splitting them into 1-3 and 3-12 periods (our initial split 
based on visual inspection) was best for the Dementia cohort 
(AUC=0.715).  
TABLE III: RANDOM FOREST  PERFORMANCE ACROSS DISEASE COHORT  
   
1-3 and 3-12 split Best split* 
Cohort 
Mort. 
rate 
(dev.)  
Mort 
rate 
(valid.)  AUC  SD AUC  SD 
Tumor 4.7 4.4 0.826 0.010 0.828 0.010 
COPD 4.9 4.8 0.811 0.009 0.814 0.009 
CHF 7.7 7.7 0.752 0.009 0.756 0.009 
Dementia 10.1 9.7 0.715 0.008 0.715 0.008 
Table 3 shows AUC and bootstrapped standard deviation of the 
validation datasets using the random forest classified with augmented 
variables. "dev." denotes development (i.e., training and tuning 
subsamples), "valid." denotes validation, “Mort.” denotes mortality.  
* The best split for the tumor, COPD and CHF was 1 and 1-12 months 
while that of the Dementia was 1-3 and 3-12 
 
These wide variations in AUC did not correlate with 
mortality rate—in fact, there appeared to be an inverse 
correlation, since the highest AUC was observed in the 
tumor cohort with the lowest mortality rate, and the lowest 
AUC in the dementia cohort with the highest mortality rate. 
This raised the possibility that certain aspects of the disease 
cohorts, unrelated to class imbalance, had large effects on 
model performance. We hypothesized that differences in 
underlying disease severity and evolution accounted for 
these differences. To measure this, we counted the number 
of unique diagnoses coded for each patient in the 12 months 
leading up to t0, separated by outcome (dead or alive). 
Finally, we calculated the difference between the two means 
for each month. Figure 2 shows the mean number of coded 
diseases per patient on each month leading up to t0. Patients 
who ultimately died are represented by solid lines while 
ones who did not are represented with dashed lines. Patients 
who ultimately died had a significant increase in the number 
of coded diseases reflecting increasing severity with time. 
Figure 3 shows the difference in the mean number of coded 
diseases between patients with a positive outcome and ones 
with a negative outcome. This difference between the two 
groups, which can be used as proxy for difference in 
measured disease severity, was highest among the tumor 
patients followed by COPD, CHF and dementia—which 
correlated directly with the AUC of the best-performing 
random forest model. 
 
 
Fig. 2. Patterns in underlying disease severity & evolution 
  
 
Fig. 3. Difference in disease severity between events and non-events 
V. DISCUSSION 
Using nationally-representative administrative claims of 
beneficiaries across a range of different disease types, we 
developed an augmented set of variables capturing different 
aspects of a patient’s health condition. We screened multiple 
ML algorithms to find the best performing algorithm. We 
found that a RF classifier presented with an augmented set 
of variables and a balanced subsample to grow each tree i.e., 
a ‘balanced RF’ outperforms all other classifiers.  
We observed large improvements in model performance 
with the augmented set of variables developed for this study, 
using a combination of domain knowledge and statistical 
cross-validation. This was likely the result of three key 
factors. First, these variables quantified disease severity by 
using counts of encounters rather than simply presence or 
absence of the medical encounter or disease. Second, they 
capture disease progression over time, by splitting the 
variables into two discrete periods. These two attributes lead 
to an improved ability to learn differences between patients 
with increases in healthcare utilization and disease severity 
near the end of life, and patients who show low utilization 
and disease severity levels. Third, we added commonly 
overlooked yet clinically significant variables, including 
patients’ ability to function independently, which is known 
to be highly correlated to prognosis but ignored by 
traditional comorbidity measures.   
 Classifier performance was affected by the pattern of 
recorded comorbidity in the patients studied. While it is 
commonly believed that degree of class imbalance is a 
major determinant of classification performance [17], almost 
all the classifiers produced better predictions for the tumor 
cohort, despite the fact that it suffered from the highest class 
imbalance relative to all other disease cohorts. This was 
likely because the time trend and level of recorded 
diagnoses in patients who went on to die were quite 
different than patients who did not. In general, the bigger the 
difference in disease severity between the patients with the 
positive outcome and the ones with the negative outcome, 
the better the predictions were . 
Our study had at least two major limitations. First, a 
dataset that accurately captures individual diagnoses and 
medical encounters of patients is a complex individual-level 
time series dataset, and creating a feature set from these 
fine-grained inputs requires a number of choices that are 
often somewhat arbitrary. There are about 25 million 
possible combinations4 of diagnoses, dates, and encounter 
patterns and it would not be feasible to screen all possible 
features for inclusion in the model. Thus choices must be 
made, relying on content expertise rather than more 
formalized feature selection techniques. It is possible that a 
different set of variables, which incorporates different 
 
4 Number is calculated by multiplying the number of possible ICD codes 
with the number of days in a year and the number of different medical 
encounters that patient can have.  
choices of variables, might have outperformed the proposed 
one. Future work could focus on formalizing these choices 
Second, our results depend to a large extent on the ML 
screening process and the choice of tuning parameter values. 
It may be true that the screening algorithm we used did not 
find the globally optimal classifier, tuning parameters and 
class balancing techniques. However, since the RF family 
completely outperformed all others and variations within the 
same family of classifiers yield minimal changes in 
performance, we believe this model is the best classifier for 
this and similar large administrative claims datasets.  
   
VI. CONCLUSION 
Accurate assessment of patients’ likelihood to survive on 
the short run is crucial in guiding physician and patient 
decisions as well as population health management efforts. 
Prior studies have produced prognostic tools that are not 
practical in a real life setting because of technical and 
practical limitations.  In this paper we used routinely 
collected administrative data to construct a unique feature 
set that captures disease severity and progression and 
screened the most widely used ML algorithms to create a 
prognostic tool that outperformed ones commonly used in 
medical literature.  Eventually, similar classifiers could be 
used to feedback prognostic information to clinicians or 
policy-makers to identify patients at high risk of short-term 
mortality, and allow honest patient-physician discussions 
about end of life care and treatment options.   
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